Effect of Daikenchuto (TU 100), a Gastrointestinal Nerve Modulator, on Rectal Sensation in Patients With Irritable Bowel Syndrome

Trial Profile

Effect of Daikenchuto (TU 100), a Gastrointestinal Nerve Modulator, on Rectal Sensation in Patients With Irritable Bowel Syndrome

Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Jun 2016

At a glance

  • Drugs TJ 100 (Primary)
  • Indications Irritable bowel syndrome
  • Focus Pharmacodynamics
  • Sponsors Tsumura
  • Most Recent Events

    • 07 Apr 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 23 May 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Aug 2014 to 1 Aug 2015.
    • 04 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top